A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Name: A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
Published: 2015
License: Public Domain

Celgene · 2015

ClinicalTrials.gov · Datasets · License: Public Domain · 2015

Open Source ↗

fatigue infection multiple-myeloma

multiple myeloma, pomalyst, teratogenicity, bone marrow suppression, thromboembolism, peripheral neuropathy, infection, tumour lysis syndrome, somnolence, depressed level of consciousness, confusion, fatigue

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 844303
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.